Pfizer led the Roche-backed antibody developer’s series C round, which boosted its overall funding to $66m.
Month: January 2015
Nestlé feeds $65m to Seres
Nestlé Health Science, a nutritional therapy subsidiary of food and beverage company Nestlé, invested $65m in US-based biotechnology company Seres Health yesterday. Seres secured the series D funding just one month after a $48m series C round backed by undisclosed investors. The company previously raised $10m in a June 2014 series B round that featured… Continue reading Nestlé feeds $65m to Seres
Clark retires from Fidelity
Simon Clark, who has also served as chairman of the BVCA, has left Fidelity’s European venture capital unit after 15 years as managing partner.
Glassdoor recruits Google for series F
Google’s growth equity unit has led a round that has boosted the recruitment platform’s overall funding to about $160m.
View opens up for $75m round
The GE and Corning-backed energy-efficient window manufacturer has raised almost $29m of a $75m late-stage equity round.
NetDragon fires up IDG-backed education unit
Mobile internet company NetDragon’s online education subsidiary has raised $52.5m in a series A round supported by IDG and Alpha Animation.
Markets to find Spark after $86m IPO
Spark Therapeutics, a spin-out of Children’s Hospital of Philadelphia, is developing gene therapy treatments for a rare blinding disorder and haemophilia.
SoftBank assists X.ai for $9.2m series A
X.ai, which is building an artificial intelligence-powered scheduler for meetings, has now raised more than $11m in total, after closing a second SoftBank-backed round.
Softbank moves back in for Reonomy series B
Commercial real estate data and analytics provider Reonomy has secured $13m in a SoftBank-led round that will be used to support additional hiring.
Eli Lilly leads $15m Symic series A
Symic Biomedical, which is developing treatments for the non-cellular part of tissue, has raised $15m in a round featuring Eli Lilly and Mitsui.
DiResta finds Haven from O’Reilly
Renee DiResta has left corporate venturing unit O’Reilly Alphatech to take up a position at startup Haven, and will continue to invest as an angel investor.
Chiasma recovers to secure $33.8m
Following a cancelled deal with pharmaceutical company Roche, the Ofer-backed pharmaceutical company has raised the first tranche of a planned $56.3m series E round.
Moderna Therapeutics raises largest ever biotech funding round
AstraZeneca and Alexion both contributed to the $450m round, the biggest ever raised by a privately held drug developer.
Cancer drug developer Aduro raises $51.4m
Johnson & Johnson-backed oncology company Aduro has closed a series D round that will be used to advance its pipeline of drug candidates.